266 related articles for article (PubMed ID: 30519336)
1. The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer.
Wei XL; Wu QN; Chen DL; Zeng ZL; Lu JB; Liu ZX; Ju HQ; Ren C; Pan ZZ; Wang FH; Xu RH
J Cancer; 2018; 9(23):4325-4333. PubMed ID: 30519336
[No Abstract] [Full Text] [Related]
2. Heterogeneity of PD-L1 expression and CD8 lymphocyte infiltration in metastatic colorectal cancer and their prognostic significance.
Xin H; Zhou C; Wang G; Liu Y; Zhang J; Liu Y; Li B; Zhang J; Su M; Li Z; Wang G
Heliyon; 2023 Feb; 9(2):e13048. PubMed ID: 36814622
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
[TBL] [Abstract][Full Text] [Related]
4. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
5. Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability.
Cho J; Lee J; Bang H; Kim ST; Park SH; An JY; Choi MG; Lee JH; Sohn TS; Bae JM; Kang WK; Kim S; Kim KM
Oncotarget; 2017 Feb; 8(8):13320-13328. PubMed ID: 28076847
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer.
Calik I; Calik M; Turken G; Ozercan IH; Dagli AF; Artas G; Sarikaya B
Medicina (Kaunas); 2019 Oct; 55(11):. PubMed ID: 31683723
[No Abstract] [Full Text] [Related]
7. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
8. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers.
Kim JH; Park HE; Cho NY; Lee HS; Kang GH
Br J Cancer; 2016 Aug; 115(4):490-6. PubMed ID: 27404452
[TBL] [Abstract][Full Text] [Related]
10. Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability.
Ma C; Patel K; Singhi AD; Ren B; Zhu B; Shaikh F; Sun W
Am J Surg Pathol; 2016 Nov; 40(11):1496-1506. PubMed ID: 27465786
[TBL] [Abstract][Full Text] [Related]
11. Role of Mismatch Repair Deficiency Status and Microsatellite Instability in Relation to the Expression of Immune Checkpoint Proteins in Colorectal Cancer.
Sharma A; Raphael V; Lyngdoh BS; Harris C; Jagtap VK
Cureus; 2023 Aug; 15(8):e43571. PubMed ID: 37719521
[TBL] [Abstract][Full Text] [Related]
12. The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability
Jin Z; Yoon HH
J Gastrointest Oncol; 2016 Oct; 7(5):771-788. PubMed ID: 27747091
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
[TBL] [Abstract][Full Text] [Related]
14. Immune profiling of microsatellite instability-high and polymerase ε (
Wang C; Gong J; Tu TY; Lee PP; Fakih M
J Gastrointest Oncol; 2018 Jun; 9(3):404-415. PubMed ID: 29998005
[TBL] [Abstract][Full Text] [Related]
15. Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases.
Manson QF; Schrijver WAME; Ter Hoeve ND; Moelans CB; van Diest PJ
Clin Exp Metastasis; 2019 Feb; 36(1):29-37. PubMed ID: 30547271
[TBL] [Abstract][Full Text] [Related]
16. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors.
Song JS; Kim D; Kwon JH; Kim HR; Choi CM; Jang SJ
Front Oncol; 2019; 9():1055. PubMed ID: 31681591
[No Abstract] [Full Text] [Related]
18. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
[TBL] [Abstract][Full Text] [Related]
19. Programmed death ligand 1 expression and CD8
Zhou J; Gong Z; Jia Q; Wu Y; Yang ZZ; Zhu B
Biochem Biophys Res Commun; 2018 Apr; 498(4):751-757. PubMed ID: 29526752
[TBL] [Abstract][Full Text] [Related]
20. Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival.
Svensson MC; Borg D; Zhang C; Hedner C; Nodin B; Uhlén M; Mardinoglu A; Leandersson K; Jirström K
Front Oncol; 2019; 9():136. PubMed ID: 30931254
[No Abstract] [Full Text] [Related]
[Next] [New Search]
